Pfizer Receives European Approval To Expand Use Of Prevenar 13* To Adults Aged 18 To 49 Years For The Prevention Of Invasive

  Pfizer Receives European Approval To Expand Use Of Prevenar 13* To Adults
  Aged 18 To 49 Years For The Prevention Of Invasive Pneumococcal Disease

Business Wire

NEW YORK -- July 10, 2013

Pfizer Inc. (NYSE: PFE) announced today the company’s pneumococcal conjugate
vaccine, Prevenar 13* (pneumococcal polysaccharide conjugate vaccine
[13-valent, adsorbed]), received European approval for an expanded indication
to include adults aged 18 to 49 years for active immunization for the
prevention of invasive disease caused by vaccine-type Streptococcus pneumoniae
(S. pneumoniae).^1 Previously approved in the European Union (EU) for use in
infants, young children and adolescents aged 6 weeks to 17 years, as well as
adults 50 years of age and older, Prevenar 13 is now the only pneumococcal
vaccine in the EU that offers protection against invasive disease from infancy
through adulthood.^1 The European Commission is the first to approve Prevenar
13 to offer protection against invasive disease at all stages of life.

“Prevenar 13 has been administered to millions of individuals around the
world, and today’s European approval for the expanded use of Prevenar 13 is a
testament to Pfizer’s continued commitment to developing innovative vaccines
that can help prevent serious – and sometimes fatal – disease through every
stage of life,” said Emilio Emini, Ph.D., chief scientific officer, Vaccine
Research, Pfizer.

The European Commission’s decision to approve this label expansion for
Prevenar 13 followed the submission and review of data from an open-label
Phase 3 trial of the vaccine in healthy adults aged 18 to 49 years.^2 The
study – which met all primary and secondary objectives – showed that Prevenar
13 is at least as immunogenic in this age group as it is in adults 60 to 64
years of age, as measured one month after vaccination.^2 Furthermore, Prevenar
13 showed a favorable safety profile and was generally well tolerated.^2

“Adults aged 18 to 49 years with certain underlying medical conditions may
benefit in particular from vaccination with Prevenar 13 because of an
increased risk of pneumococcal disease,” said Luis Jodar, Ph.D., vice
president, Vaccines Global Medicines Development Group, Pfizer. “Pfizer will
continue to partner with health authorities worldwide to seek to provide
access to this important vaccine to all those at risk of the disease.”

Prevenar 13, or Prevnar 13 as it is called in the United States, Canada and
Taiwan, was first introduced for use in infants and young children in December
2009 in the EU. It is now approved in more than 120 countries worldwide for
use in infants and young children, and in more than 80 countries for use in
adults 50 years of age and older.

Pneumococcal Disease (PD)

Pneumococcal Disease is a group of illnesses caused by the bacterium S.
pneumoniae, also known as pneumococcus.^3 It can affect people of all ages,
although older adults, young children and individuals with certain chronic
medical conditions are at heightened risk.^4,5 PD is associated with
significant morbidity and mortality.^4,5 Invasive manifestations of the
disease include bacteremia (bacteria in the blood) and meningitis (infection
of the tissues surrounding the brain and spinal cord).^3,6

Indication for Prevenar 13 in Europe

Prevenar 13 is approved in the EU for the prevention of invasive disease,
pneumonia and acute otitis media caused by S. pneumoniae serotypes (1, 3, 4,
5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) in children and adolescents
aged 6 weeks to 17 years.^1 It is also approved in the EU for the prevention
of invasive disease caused by 13 S. pneumoniae serotypes (single dose) in
adults 18 years of age and older. For the full prescribing information for
Prevenar 13 in the EU, please see the Summary of Product Characteristics.

Indication for Prevnar 13 in the United States

  *Prevnar 13 is a vaccine approved for children 6 weeks through 17 years of
    age for the prevention of invasive disease caused by 13 S. pneumoniae
    strains (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F), and for
    children 6 weeks through 5 years for the prevention of otitis media caused
    by 7 of the 13 strains (4, 6B, 9V, 14, 18C, 19F, and 23F)^7
  *Based upon immune responses to the vaccine, Prevnar 13 is also approved
    for adults 50 years of age and older for the prevention of pneumococcal
    pneumonia and invasive disease caused by the 13 vaccine strains^7
  *Prevnar 13 is not 100% effective and will only help protect against the 13
    strains included in the vaccine^7
  *Effectiveness when given less than 5 years after a pneumococcal
    polysaccharide vaccine is not known^7

Important Safety Information

  *Prevnar 13 should not be given to anyone with a history of severe allergic
    reaction to any component of Prevnar 13 or any diphtheria
    toxoid–containing vaccine
  *Children and adults with weakened immune systems (e.g., HIV infection,
    leukemia) may have a reduced immune response
  *A temporary pause of breathing following vaccination has been observed in
    some infants born prematurely
  *The most commonly reported serious adverse events in infants and toddlers
    were bronchiolitis (an infection of the lungs) (0.9%), gastroenteritis
    (inflammation of the stomach and small intestine) (0.9%), and pneumonia
    (0.9%)
  *In children 6 weeks through 17 years, the most common side effects were
    tenderness, redness, or swelling at the injection site, irritability,
    decreased appetite, decreased or increased sleep, and fever. Most commonly
    reported side effects in children 5 years through 17 years also included
    hives
  *In adults, immune responses to Prevnar 13 were reduced when given with
    injected seasonal flu vaccine
  *In adults, the common side effects were pain, redness, or swelling at the
    injection site, limitation of arm movement, fatigue, headache, muscle
    pain, joint pain, decreased appetite, chills, or rash
  *Ask your health care provider about the risks and benefits of Prevnar 13.
    Only a health care provider can decide if Prevnar 13 is right for you or
    your child

For the full prescribing information for Prevnar 13, please click here
http://www.pfizer.com/products/#prevnar13.

Pfizer Inc: Working together for a healthier world™

At Pfizer, we apply science and our global resources to bring therapies to
people that extend and significantly improve their lives. We strive to set the
standard for quality, safety and value in the discovery, development and
manufacture of health care products. Our global portfolio includes medicines
and vaccines as well as many of the world's best-known consumer health care
products. Every day, Pfizer colleagues work across developed and emerging
markets to advance wellness, prevention, treatments and cures that challenge
the most feared diseases of our time. Consistent with our responsibility as
one of the world's premier innovative biopharmaceutical companies, we
collaborate with health care providers, governments and local communities to
support and expand access to reliable, affordable health care around the
world. For more than 150 years, Pfizer has worked to make a difference for all
who rely on us. To learn more, please visit us at www.pfizer.com.

*Trademark. Prevnar 13™ is the trade name in the United States, Canada, and
Taiwan.

References

1. Pfizer Data on File (DOF). DRAFT Prevenar 13 Global Summary of Product
Characteristics (SmPC).

2. Pfizer Data on File (DOF). Bryant K., Frenck, R., et al. ECCMID Draft
Abstract. ePoster 736. Immunogenicity and safety of a 13-valent pneumococcal
conjugate vaccine in adults aged 18–49 years, naïve to 23-valent pneumococcal
polysaccharide vaccine. April 28, 2013.

3. Centers for Disease Control and Prevention (CDC). Pneumococcal Disease. CDC
Pink Book. 2011;16:233-248.

4. World Health Organization (WHO). 23-valent pneumococcal polysaccharide
vaccine. WHO Position Paper. Wkly Epidemiol Rec. 2008;83(42):373-384.

5. World Health Organization (WHO). Immunization, Vaccines and Biologicals.
Pneumoccocal Vaccines. April 2003.Wkly Epidemiol Rec. 2003;78(14):97-120.

6. Centers for Disease Control and Prevention. Prevention of Pneumococcal
Disease: Recommendations of the Advisory Committee on Immunization Practices
(ACIP). MMWR Recommendations and Reports. 1997;46(RR-8):1-24.

7. Prevnar 13 Prescribing Information.
http://labeling.pfizer.com/showlabeling.aspx?id=501.

Contact:

Pfizer Inc.
Media Contacts:
Andrew Widger, +44.7970.149098 (m)
Kim Bencker, +1 610.329.1340 (m)
or
Investor Contact:
Suzanne Harnett, +1 212.733.8009 (o)
 
Press spacebar to pause and continue. Press esc to stop.